Brain Stimulation for Neurological Patients

NCT03770182•Storz Medical AG

View on ClinicalTrials.gov

Summary

This is a prospective double-blind randomized placebo-controlled crossover clinical trial

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinically stable patients with probable Alzheimer's Disease (Diagnosis according to ICD-10 Criteria (F00))
•At least 3 months of stable antidementive therapy or no antidementive therapy necessary
•Signed written informed consent
•Monthly pregnancy test for women in childbearing years
•Age \>= 18 years

Exclusion Criteria

•Non-compliance with the protocol
•Pregnant or breastfeeding women
•Relevant intracerebral pathology unrelated to the Alzheimers's disease (e.g. Brain tumor)
•Hemophilia or other blood clotting disorders
•Cortisone treatment within the last 6 weeks before first treatment
•Thrombosis

Locations (1)

Medical University of Vienna

Vienna, Austria

Key Dates

Start Date

January 1, 2017

Primary Completion Date

July 27, 2022

Completion Date

July 27, 2022

Last Updated

November 22, 2023

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

NEUROLITH

DEVICE

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Brain Stimulation for Neurological Patients

Inclusion Criteria

Exclusion Criteria

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease